

# GNIPST BULLETIN 2024

(Pharmacy)



VOLUME-1, ISSUE- 3



GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



# Table of Contents

**1** Message form Director  
and Principal

**2** Latest News/ Research  
News

**3** Campus News

**4** Games



## MESSAGE FROM HONORABLE DIRECTOR


I extend my heartfelt greetings to you all. At Guru Nanak Institute of Pharmaceutical Science and Technology, we are committed to fostering an environment of academic excellence, innovation and holistic development.

Our institution is dedicated in pursuit of Pharmaceutical Sciences.

We believe in nurturing inquisitive minds, encouraging critical thinking and developing skills of our beloved students. As we continue to grow and evolve, we remain steadfast in our mission to provide quality education and promote research and innovation.

We wholeheartedly appreciate your valued presence and involvement with Guru Nanak Institute of Pharmaceutical Science and Technology.

*Prof. (Dr.) Abhijit Sengupta*



## MESSAGE FROM HONORABLE PRINCIPAL

It is my great pleasure to extend a warm welcome to you to Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST).

GNIPST is among the leading educational institutes of West Bengal aiming to provide quality pharmacy education to students.

GNIPST was established in 2005 and approved by PCI and affiliated to Maulana Abul Kalam Azad University of Technology, West Bengal. The institute is also the first pharmacy institute in West Bengal to receive accreditation from NAAC and NBA and the only private Pharmacy Autonomous institute in West Bengal. GNIPST is proud to be an NIRF Ranked Pharmacy Institute, being the 74th ranked institute in 2024.

We sincerely believe that rich values and traditions imbibed here along with proper educational facilities would carry the students to greater levels in their life.

Choose PHARMACY as a career and join with us to have a academically rewarding student life at GNIPST.

*Prof. (Dr.) Lopamudra Datta*



# RECENT RESEARCHES



**CEPI and WHO urge broader research strategy for countries to prepare for the next pandemic**

[READ MORE](#)

<https://www.who.int/news/item/01-08-2024-cepi-and-who-urge-broader-research-strategy-for-countries-to-prepare-for-the-next-pandemic>

The Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO) today called on researchers and governments to strengthen and accelerate global research to prepare for the next pandemic. They emphasized the importance of expanding research to encompass entire families of pathogens that can infect humans—regardless of their perceived pandemic risk—as well as focusing on individual pathogens. The approach proposes using prototype pathogens as guides or pathfinders to develop the knowledge base for entire pathogen families. At the Global Pandemic Preparedness Summit 2024 held in Rio de Janeiro, Brazil, WHO R&D Blueprint for Epidemics issued a report urging a broader-based approach by researchers and countries. This approach aims to create broadly applicable knowledge, tools and countermeasures that can be rapidly adapted to emerging threats. This strategy also aims to speed up surveillance and research to understand how pathogens transmit and infect humans and how the immune system responds to them.

**Falsified (contaminated) Oxymorphone Hydrochloride 40 mg identified in the WHO Region for Europe**

[READ MORE](#)

[https://www.who.int/news/item/05-08-2024-medical-product-alert-n-3-2024-falsified-\(contaminated\)-oxymorphone-hydrochloride-40mg#:~:text=This%20WHO%20Medi%20cal%20Product%20Alert,Finnish%20Medicines%20Agency%20\(FIMEA\),](https://www.who.int/news/item/05-08-2024-medical-product-alert-n-3-2024-falsified-(contaminated)-oxymorphone-hydrochloride-40mg#:~:text=This%20WHO%20Medi%20cal%20Product%20Alert,Finnish%20Medicines%20Agency%20(FIMEA),)

This WHO Medical Product Alert refers to one batch of falsified Oxymorphone Hydrochloride 40mg. The falsified product was detected in the unregulated supply chain in Finland and reported to WHO in July 2024 by the Finnish Medicines Agency (FIMEA). Oxymorphone Hydrochloride is a semi-synthetic opioid used to treat moderate to severe pain. Laboratory analysis of samples of the falsified product, however, found that the tablets contained metonitazene instead. Metonitazene is a potent psychoactive synthetic opioid drug, with no officially recognized or authorized medicinal or therapeutic use. It is under international control as a Schedule I narcotic drug following recommendations of the WHO Expert Committee on Drug Dependence in 2021.

**WHO and International Paralympic Committee team up to highlight power of assistive technology at Paris 2024 Paralympics**


[READ MORE](#)

[https://www.who.int/news/item/28-08-2024-who-and-international-paralympic-committee-team-up-to-highlight-power-of-assistive-technology-at-paris-2024-paralympics#:~:text=The%20World%20Health%20Organization%20\(WHO,the%20Paris%202024%20Paralympic%20Games,](https://www.who.int/news/item/28-08-2024-who-and-international-paralympic-committee-team-up-to-highlight-power-of-assistive-technology-at-paris-2024-paralympics#:~:text=The%20World%20Health%20Organization%20(WHO,the%20Paris%202024%20Paralympic%20Games,)

The World Health Organization (WHO) and International Paralympic Committee (IPC) are joining forces to highlight the transformative impact of assistive technology on sports during the Paris 2024 Paralympic Games. The "Equipped for equity" campaign emphasizes the crucial role of assistive technology for Paralympic athletes to advocate for concerted global action to improve access to these essential health products. Throughout the Games, WHO and IPC will leverage the Paralympics platform to share messages and information focused on the importance of assistive technology, how athletes use it, and why universal access is essential. Examples of assistive technology used by Paralympians include: running blades, wheelchairs, and release braces in archery. The "Equipped for equity" campaign will also feature personal stories from athletes who rely on assistive technology for sport and in daily life and highlight national successes in advancing access to these critical health products.

# NEW DRUG APPROVALS

## AUGUST 2024



### **Tecelra (afamitresgene autoleucel) Suspension**

- Company: Adaptimmune Therapeutics plc
- Date of Approval: August 1, 2024
- Treatment for: Synovial Sarcoma

1

### **Voranigo (vorasidenib) Tablets**

- Company: Servier Pharmaceuticals
- Date of Approval: August 6, 2024
- Treatment for: Malignant Glioma

2

### **Crexont (carbidopa and levodopa) - formerly IPX203**

- Company: Amneal Pharmaceuticals LLC
- Date of Approval: August 7, 2024
- Treatment for: Parkinson's Disease

3

### **Zurnai (nalmefene hydrochloride) Injection**

4

### **Yorvipath (palopegteriparatide) Injection**

- Company: Ascendis Pharma, Inc.
- Date of Approval: August 9, 2024
- Treatment for: Hypoparathyroidism

5

### **Enzeevu (aflibercept-abzv) Injection**

- Company: Sandoz Inc.
- Date of Approval: August 9, 2024
- Treatment for: Macular Degeneration

6

LEARN

MORE

<https://www.drugs.com/newdrugs.html>


# NEW DRUG APPROVALS

## AUGUST 2024



### Neffy (epinephrine) Nasal Spray

- Company: ARS Pharmaceuticals, Inc.
- Date of Approval: August 9, 2024
- Treatment for: Anaphylaxis

1

### Nemluvio (nemolizumab) for Injection

- Company: Galderma Laboratories, L.P.
- Date of Approval: August 12, 2024
- Treatment for: Prurigo Nodularis

2

### Livdelzi (seladelpar) Capsules

- Company: Gilead Sciences, Inc.
- Date of Approval: August 14, 2024
- Treatment for: Primary Biliary Cholangitis

3

### Niktimvo (axatilimab-csfr) Injection

- Company: Incyte and Syndax Pharmaceuticals
- Date of Approval: August 14, 2024
- Treatment for: Graft-versus-host disease

4

### Lazcluze (lazertinib) Tablets

- Company: Johnson & Johnson Innovative Medicine
- Date of Approval: August 20, 2024
- Treatment for: Non Small Cell Lung Cancer

5

### Pavblu (aflibercept-ayh) Injection

- Company: Amgen Inc.
- Date of Approval: August 23, 2024
- Treatment for: Macular Degeneration


6

LEARN

MORE

<https://www.drugs.com/newdrugs.html>


# Latest Generic Drug Approvals



## **TRAMETINIB DIMETHYL SULFOXIDE TABLETS 0.5 MG (BASE) AND 2 MG (BASE)**

- **Approved:** August 6, 2024 - Novugen Pharma (USA) LLC
- **Treatment for:** Cancer
- **Generic for:** **Mekinist**

1

2

## **LOFEXIDINE HYDROCHLORIDE TABLETS 0.18MG (BASE)**

- **Approved:** August 20, 2024 - Indoco Remedies Ltd.
- **Treatment for:** Opiate Withdrawal
- **Generic for:** **Lucremyra**



## **RILUZOLE ORAL SUSPENSION 50 MG/10 ML**

- **Approved:** August 22, 2024 - Alkem Laboratories Ltd.
- **Treatment for:** Amyotrophic Lateral Sclerosis
- **Generic for:** **Tiglutik**

3



## **METHYLNALTREXONE BROMIDE SUBCUTANEOUS SOLUTION 8 MG/0.4 ML AND 12 MG/0.6 ML**

- **Approved:** August 26, 2024 - Actavis Pharma, Inc.
- **Treatment for:** Opioid-Induced Constipation
- **Generic for:** **Relistor**

5

4



## **AMANTADINE HYDROCHLORIDE EXTENDED RELEASE CAPSULES 68.5MG (BASE)**

- **Approved:** August 26, 2024 - Zydus Pharmaceuticals (USA) Inc.
- **Treatment for:** Parkinson's Disease
- **Generic for:** **Gocovri**

LEARN

MORE

<https://www.drugs.com/newdrugs.html>

# DISEASE OUTBREAK NEWS



## 1. Acute encephalitis syndrome due to Chandipura virus - India (23 August, 2024)



<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON529>

### Situation at a glance

Between early June and 15 August 2024, the Ministry of Health and Family Welfare of the Government of India reported 245 cases of acute encephalitis syndrome (AES) including 82 deaths (CFR 33%). Of these, 64 are confirmed cases of Chandipura virus (CHPV) infection. CHPV is endemic in India, with previous outbreaks occurring regularly. However, the current outbreak is the largest in the past 20 years. CHPV is a member of the Rhabdoviridae family and is known to cause sporadic cases and outbreaks of AES in western, central and southern parts of India, especially during the monsoon season. It is transmitted by vectors such as sandflies, mosquitoes and ticks. The case-fatality ratio from CHPV infection is high (56-75%), and there is no specific treatment or vaccine available. Survival can be increased with early access to care and intensive supportive care of patients. Although authorities are working to control CHPV transmission, further transmission of the virus is possible in the coming weeks, as the monsoon season is creating favorable conditions for vector populations in the affected areas. WHO recommends vector control, and protection against bites of sandflies, mosquitos, and ticks, to prevent further spread of CHPV.

## 2. Mpox – African Region (22 August, 2024)



<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON528>

### Situation at a glance

On 14 August 2024, the WHO Director-General determined that the upsurge of mpox in the Democratic Republic of the Congo and a growing number of countries in Africa constitutes a Public Health Emergency of International Concern (PHEIC) under the International Health Regulations (2005) (IHR), the highest level of alarm under the IHR. Here we describe the latest countries in the region newly reporting cases since the start of the multi-country outbreak in 2022. The clade Ib MPXV outbreak, which began in September 2023 in the Democratic Republic of the Congo, is having an increasing number of cases in the country and also expanding to neighbouring countries. Burundi, Kenya, Rwanda and Uganda have each reported their first mpox cases. Several of these cases have travel links to eastern parts of the Democratic Republic of the Congo and each of these countries has identified clade Ib monkeypox virus (MPXV). Based on available epidemiological data, this clade has been spreading rapidly among adults through close physical contact, including sexual contact identified within networks of sex workers and their clients. As the virus spreads further, the affected groups are changing, with the virus also taking hold within households and other settings. Additionally, Cote d'Ivoire is reporting cases of clade II mpox for the first time since the start of the multi-country outbreak in 2022.

# Faculty Achievements



## Congratulations! Dr. Moumita Chowdhury

Congratulations to **Ms. Moumita Chowdhury** on earning her Doctor of Philosophy (PhD)! Her dedication and hard work have culminated in this outstanding achievement. We are incredibly proud of her success and look forward to her continued contributions to our academic community. Well done, **Dr. Chowdhury!** *(29th June, 2024)*



## Congratulations! Ms. Priyanka Ray

Congratulations to **Ms. Priyanka Ray** for successfully **defending her PhD thesis!** Her dedication and hard work have led to this significant achievement. We are immensely proud of her accomplishment and look forward to the valuable contributions she will continue to make. *(04th September, 2024)*

## Congratulations! Dr. Debabrata Ghosh Dastidar

Congratulations to Dr. Debabrata Ghosh Dastidar on the publication of his paper, "***Staphylococcus aureus major cell division protein FtsZ assembly is inhibited by silibinin, a natural flavonolignan that also blocked bacterial growth and biofilm formation.***" This significant contribution advances our understanding in the field. Well done, Dr. Ghosh Dastidar! *(31st August, 2024)*



Staphylococcus aureus major cell division protein FtsZ assembly is inhibited by silibinin, a natural flavonolignan that also blocked bacterial growth and biofilm formation.

# Campus News

10 students (B. Pharm) of our institution are shortlisted for the final round of interview on MYMD HEALTHCARE PVT. LTD as Registered Pharmacist.



Ms.Trina Pramanik (B.Pharm) & Ms. Malufa Yasmin (B.Pharm) have been selected for the Production Department & QA Department of Sun Pharma as an intern on SUN PHARMA SIKKIM.



Our institute organized Exclusive Orientation Program for the Opportunity in Officer Cadre of Indian Air Force.



“প্রাক স্বাধীনতা দিবসের চলমান মহোৎসব” Rally was inspired by the leadership and vision demonstrated by Honorable Director (Prof.) Dr. Abhijit Sengupta and Principal (Prof.) Dr. Lopamudra Dutta. it was initiated from the main entrance of the institute in the GNCC (Guru Nanak College Campus) and from Panhati, Sodepur, it exceeded to Baranagar Metro Station (around 5.4 K.M).



The NDLI Club of Guru Nanak Institute of Pharmaceutical Science and Technology hosted a workshop on "Use of E-Resources for Research Activity", where we gained valuable insights from Mr. Mahendranath Sarkar, Training Head at Informatics. This workshop was a fantastic opportunity for students to enhance their research skills and make the most of digital resources.



Nabachetana Yoga and Meditation Club of Guru Nanak Institute of Pharmaceutical Science and Technology in collaboration with the Himalayan Meditation, West Bengal organized a 15 days workshop on “Life Management with Himalayan Meditation” from 16th August to 30th August, 2024.



GNIPST organized a Friendly Football Match on August 15th which was an action-packed game featuring our GNIPST Alumni team versus the current GNIPST students team.



The Entrepreneur Development Cell (EDC) and the Institutions Innovation Council (IIC) of Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST) jointly organised the GNIPST Intra-college Hackathon 2024 (GNIPST Innovation Challenges 2024) for the students of GNIPST.



Bramha Kumaries came to our institute to celebrate Raksha Bandhan with our Faculties and staff.



## OUR PATHFINDER Or OUR MOTIVATORS



**Prof. K. N. Udupa (1920-1992)**

- **Known for:** Integrating traditional Indian medicine with modern pharmacy education
- **Contributions:** Prof. K. N. Udupa was a prominent figure in the Indian pharmaceutical and medical education sectors. He was instrumental in promoting the integration of Ayurveda with modern medicine and pharmacy. Udupa was associated with the Institute of Medical Sciences at Banaras Hindu University and played a vital role in advancing research in both modern and traditional medicine.
- **Legacy:** Udupa's efforts have had a lasting impact on the way pharmacy education incorporates traditional Indian medicine, contributing to a more holistic approach to healthcare in India.

- **Known as:** The "Father of Pharmacy Education in India"
- **Contributions:** Mahadeva Lal Schroff was a pioneer in establishing formal pharmacy education in India. He founded the first pharmacy college in the country, the Banaras Hindu University (BHU) College of Pharmacy, in 1937. Schroff played a crucial role in the development of the pharmaceutical sciences curriculum and was instrumental in founding the Indian Pharmaceutical Association (IPA).
- **Legacy:** Schroff's work laid the foundation for modern pharmacy education in India, and his vision continues to influence pharmacy practice and education in the country.



**M. L. Schroff (1902-1971)**



**William Procter Jr. (1817-1874)**

- **Known as:** The "Father of American Pharmacy"
- **Contributions:** Procter was a pioneering pharmacist, educator, and author. He was one of the founding members of the American Pharmaceutical Association (now the American Pharmacists Association) and served as its first secretary. His textbook, "Practical Pharmacy," was a seminal work in the field, and he was instrumental in establishing formal education for pharmacists in the United States.
- **Legacy:** Procter's influence on pharmacy education set the foundation for modern pharmacy practice and education in the U.S.

# Game Time

## Word Making

|   |   |   |   |   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | C | F | Y | U | O | H | L | G | D | E | W |
| P | H | A | R | M | A | C | O | L | O | G | Y |
| A | R | N | P | W | D | T | S | L | M | K | L |
| R | O | A | S | S | A | Y | R | V | E | H | K |
| A | M | T | A | B | L | E | T | Q | P | L | I |
| C | A | O | S | Q | K | M | U | I | R | A | C |
| E | T | M | B | N | T | H | J | Q | A | X | H |
| T | O | Y | V | W | F | N | O | T | Z | Y | K |
| A | G | R | A | N | U | L | E | S | O | R | D |
| M | R | C | Q | O | J | D | L | B | L | R | T |
| O | A | U | T | O | C | L | A | V | E | Y | F |
| L | P | R | T | H | J | T | A | V | L | W | H |
| W | H | I | S | T | A | M | I | N | E | B | J |
| D | Y | H | X | U | I | O | W | S | Q | Z | C |

All the Words are related to the pharma field

*Stay tuned for to the next edition for a shout out to fastest correct answers!*

**Submit your answer**



SCAN  
ME


or



CLICK  
HERE

# Game Time

## Answer for Crossword PH-2



GNIPST BULLETIN 2024

### Cheers to the Victor!

Volume -1, Issue -2



**Debjit Dhar**

B.Pharm, 5th Semester

Guru Nanak Institute of Pharmaceutical Science and Technology

# Editorial Board

## Editor- in- Chief

*Prof. (Dr.) Abhijit Sengupta*

## Managing Editors

*Prof. (Dr.) Lopamura Datta*

### Associate Editors

*Mr. Tushar Adhikari*

*Ms. Manjarima Ganguli*

### Editorial Board Members

*Mrs. Indrani Banerjee Chakraborty*

*Mr. Arpan Dutta*

*Ms. Ananya Chandra*

*Ms. Parnasree Chakraborty*

*Ms. Lopamudra Saha*

*Mr. Sarthak Saha*



## COURSES OFFERED

### PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

### PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

### PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

GNIPST BULLETIN 2024



**Latest news**

[www.gnipst.ac.in](http://www.gnipst.ac.in)

[www.facebook.com](http://www.facebook.com)

[www.instagram.com](http://www.instagram.com)

[www.linkedin.com](http://www.linkedin.com)

[www.youtube.com](http://www.youtube.com)

[api.whatsapp.com](http://api.whatsapp.com)